Nuclear medicine in primary breast cancer imaging

Clinical Radiology

Volumn 57, Issue 7, 2002, Pages 565-574

  Gopalan, D ^a   Bomanji, J B ^a   Costa, D C ^a   Ell, P J ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Breast cancer imaging; Positron emission tomography (PET) imaging; Radioimmunoscintigraphy; Scintimammography; Sentinel lymphnode scintigraphy; Tumour imaging

Indexed keywords

AMINO ACID; ARCITUMOMAB; CARCINOEMBRYONIC ANTIBODY; DEOXYGLUCOSE; GALLIUM CITRATE GA 67; HORMONE; LIGAND; MEDRONATE TECHNETIUM TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 170H.82; MONOCLONAL ANTIBODY B.72.3 IN 111; ONCOSCINT; PENTETATE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; PERTECHNETIC ACID TC 99M; RADIOISOTOPE; TECHNETIUM SULFUR COLLOID TC 99M; TETROFOSMIN TC 99M; THALLIUM 201; TRACER; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; DRUG HALF LIFE; FEMALE; HUMAN; ISOTOPE LABELING; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MEDICINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW;

EID: 0036665041     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1053/crad.2001.0803     Document Type: Review

References (104)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-1059.
2. Harris KM, Vogel VG. Breast cancer screening. Cancer Metastasis Rev 1997;16:231-262.
3. Mann BD, Giuliano AE, Bassett LW, et al. Delayed diagnosis of breast cancer as a result of normal mammograms. Arch Surg 1983;118:23-25.
4. Kopans DB. The positive predictive value of mammography. AJR Am J Roentgenol 1992;158:521-526.
5. Kopans DB. Breast Imaging. Philadelphia: JB Lippincott, 1989.
6. Zonderland HM. The role of ultrasound in the diagnosis of breast cancer. Semin Ultrasound CT MR 2000;21:317-324.
7. Liberman L. Percutaneous miaging-guided core breast biopsy: state of the art at the Millenium. AJR Am J Roentgenol 2000;174: 1191-1199.
8. Lee CH, Smith RC, Levine JA, Troiona RN, Tocino I. Clinical usesfulness of MR imaging of the breast in the evaluation of problematic mammograms. AJR Am J Roentgenol 1999;1173: 1323-1329.
9. Goldenberg DM, Kim EE, DeLand FH, et al. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 1980;40:2984-2992.
10. Lind P, Smola MG, Lechner P, et al. The immunoscintigraphic use of Tc -99 m-labelled monoclonal antibodies in patients with suspected primary, recurrent and metastatic breast cancer. Int J Cancer 1991;47:865-869.
11. Goldenberg DM, Abdel-Nabi H, Sullivan CL, et al. Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. Cancer 2000;89:104-115.
12. 2 in the preoperative detection of clinical and subclinical lymphnode metastases in breast cancer patients. Int J Cancer 1988;9:89-95.
13. mTc SM3 radioimmunoscintigraphy. Acta Oncol 1996;35:319-321.
14. Hayes DF, Noska MA, Kufe DW, Zalutsky MR. Effect of radioindineation on the binding of monoclonal antibody DF3 to breast carcinoma cells. Nucl Med Biol 1998;15:235-241.
15. mTc and radioiodine. Cancer Res 1994;54:4162-4168.
16. mTc. Nuklearmedizin 1995;34:197-202.
17. 2 fragments. Nucl Med Biol 1991;20:325-335.
18. 111In labelled monoclonal antibody against a mucin like antigen. Cancer Res 1990;50:927-931.
19. Lamki M, Buzdar AV, Singletonj SE, et al. Indium 111-labeled B72 monoclonal antibody in the detection and staging of breast cancer. A phase 1 study. J Nucl Med 1991;32:1326-1332.
20. McQuarrie SA, MacLean GD, Boniface GR, Golberg K, McEwan AJ. Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99 m labelled monoclonal antibody 170H.82: report of a phase II study. Eur J Nucl Med 1997;24: 381-389.
21. 201thallous chloride. Radiology 1978;129: 497-500.
22. 201 TI uptake in tumours. Eur J Nucl Med 1989;15:376-379.
23. 201 thallium scintigraphy. Cancer Lett 1988;40:161-168.
24. Waxman AD, Ramanna L, Memsic ED, et al. Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 1993;34:18-23.
25. 201T1 scintigraphy with mammography in the diagnosis of breast cancer. J Nucl Med 1993;34:2095-2100.
26. 201T1 scintigraphy. Br J Radiol 1995;68:1052-1057.
27. 201T1. Clin Nucl Med 1992;17:171-176.
28. Chiu ML, Kronage JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis [2 methoxy-isobutyl isonitrile] technetium in cultured mouse fibroblasts. J Nucl Med 1990;31:1646-1653.
29. Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug resistant P glycoprotein with an organo technetium complex. Can Res 1993;53:977-984.
30. Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in paients with suspicion of carcinoma of the breast. J Am Coll Surg 1994;178:491-497.
31. Khalkhali I, Diggles LE, Taillefer R, et al. Procedure guideline for breast imaging. J Nucl Med 1999;40:1233-1235.
32. mTc MIBI: a comparitive study with mammography and ultrasonography. Nucl Med Commun 1994;15:604-612.
33. Kao C, Wang S, Liu T. The use of Tc-99 m isonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 1994;21:432-436.
34. mTc sestamibi mammoscintigraphy of breast masses: early and delayed imaging. Nucl Med Commun 1995;16:150-156.
35. Taillefer R, Robidoux A, Lambert R, et al. Technitium 99 m-sestamibi prone scintimammography to detect primary breast cancer and axillary node involvement. J Nucl Med 1995;36: 1758-1765.
36. Khalkhali I, Cutrone JA, Mena IG, et al. Tc-99 m sestamibi scintimmamography of breast lesions: clinical and pathological follow up. J Nucl Med 1995;36:1784-1789.
37. Villanueva-Meyer J, Leonard MH Jr, Briscoe LJE, et al. Mammoscintigraphy with technetium-99-sestamibi in suspected breast cancer. J Nucl Med 1996;37:926-929.
38. Palmedo H, Schomburg A, Grunwald F, et al. Scintimammography with Tc-99 m MIBI in patients with suspicion of primary breast cancer. Nucl Med Biol 1996;23:681-684.
39. Maffioli L, Agresti R, Chiti A, et al. Prone scintimammography in patients with nonpalpable breast lesions. Anticancer Res 1996;16: 269-1273.
40. Clifford EJ, Lugo-Zamudio C. Scintimammography in the diagnosis of breast cancer. Am J Surg 1996;172:483-486.
41. mTc- MIBI scintimammography to the diagnosis of non-palpable breast lesions in relation to mammographic probability of malignancy. Anticancer Res 1997;17:677-1681.
42. Buscombe JR, Cwikla JB, Thakrar DS, et al. Uptake to Tc-99 m MIBI related to tumor size and type. Anticancer Res 1997;17: 1693-1694.
43. mTc[V] DMSA scintigraphy in evaluation of breast mass lesions. Anticancer Res 1997;17:599-1605.
44. mTc MIBI scintimammorgraphy in diagnosis of breast cancer; using surgical histopathologic diagnosis as the gold standard. Anticancer Res 1997;27:1695-1698.
45. Becherer A, Helbich T, Staudenherz A, et al. The diagnostic value of planar and SPET scintimammography in different age groups. Nucl Med Commun 1997;18:710-718.
46. mTc MIBI scintimammography. Anticancer Res 1997;17:1631-1634.
47. mTc MIBI scintimammography and contrast enhanced magnetic resonance imaging for the evaluation of indeterminate mammograms. Eur J Nucl Med 1997;24:1221-1229.
48. mTc MIBI scintimammorgraphy. Radiology 1997;202:421-429.
49. mTc sestamibi breast scintigraphy. Tumori 1997;83:520-522.
50. Mekhmandarov S, Sandmabnk J, Cohen M, et al. Technitium-99 m MIBI scintimammography in palpable and nonpalpable breast lesions. J Nucl Med 1998;39:86-90.
51. Palmedo H, Biersack HJ, Lastoria S, et al. Scintimammography with technetium-99 m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med 1999;25: 375-385.
52. Khalkhali I, Villanueva-Meyer J, Edell SL, et al. Diagnostic accuracy of Tc-99 m-Sestamibi breast imaging: multicentre trial results. J Nucl Med 2000;41:1973-1979.
53. mTc sestamibi in imaging breast cancer. Semin Nucl Med 1997;27:40-54.
54. Buscombe JR, Cwikla JB, Holloway B, Hilson AJW. Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. J Nucl Med 2000;42:3-8.
55. Scopinaro F, Schillaci O, Scarpini M, et al. Technitium-99 m sestamibi: indicator of breast cancer invasiveness. Eur J Nucl Med 1994;21:984-987.
56. Buscombe JR, Cwikla JB, Thakrar DS, et al. uptake of 99 m Tc-MIBI related to tumour size and type. Anticancer Res 1997;17: 1693-1694.
57. Klaus AJ, Klingensmith WC, Parker SH, et al. Comparative value of 99 mTc-sestamibi scintimammography and sonography in the diagnostic workup of breast masses. AJR Am J Roentgenol 2000;174:1779-1783.
58. Rimbaldi PF, Mansi L, Procaccini E, et al. Breast cancer detection with Tc-99 m Tetrofosmin. Clin Nucl Med 1995;20:703-705.
59. Younes A, Songadele JA, Maublant J, et al. Mechanism of uptake of Technetium-tetrofosmin. II. Uptake into isolated adult rat heart mitochondria. J Nucl Cardiol 1995;2:327-323.
60. Ballinger JR, Banneman J, Boxen I, et al. Tc-99 m-Tetrofosmin as a substrate for p-glycoprotein: in vivo studies in multidrug-resistant breast tumour cells. J Nucl Med 1996;37:1578-1581.
61. de Jong M, Bernard BE, Breeman BE, et al. Comparison of uptake of Tc-99 m-MIBI, Tc-99 m-tetrofosminand Tc-99 m-Q12 into human breast cancer cell lines. Eur J Nucl Med 1996;23:1361-1366.
62. Mansi L, Rambakli PF, Procaccini E, et al. Scintimammography with Technetium-99 m tetrofosmin in the diagnosis of breast cancer and lymph node metastases. Eur J Nucl Med 1996;23:932-939.
63. mTc-tetrofosmin scintigraphy in the evaluation of palpable breast masses. Nucl Med Comm 1997;18:118-121.
64. mTc Tetrofosmin scintimammography. Radiology 1997;205: 214-220.
65. mTc-tetrofosmin scintigraphy to evaluate breast lesion. Anticancer Res 1997;27: 1619-1626.
66. Schillaci O, Scopianaro F, Danieli R, et al. Scintimammography with Technetium- 99 m tetrofosmin in suspected breast cancer. Anticancer Res 1997;17:1623-1626.
67. Lind P, Umschaden HW, Forsthuber E, et al. Scintimammography using Technetium- 99 m tetrofosmin. Acta Med Austrica 1997;24: 50-54.
68. mTc-tetrofosmin scintimammography in the diagnosis of malignant breast masses and axillary lymph node involvement. A comparative study between mammography and histopathology. Eur J Surg 1999;165:1147-1153.
69. mTc sestamibi scintigraphy to evaluate suspicious breast lesions. Eur J Nucl Med 1999;26:1553-1559.
70. Subramanian G, McAfee jG, Blair AJ, et al. Technetium- 99 m-methylene diphosphonate a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 1975;16: 744-755.
71. mTc-polyphosphate. J Nucl Med 1974;15:1054-1956.
72. mTc-methylene diphosphonate scintimammography to image primary breast cancer. J Nucl Med 1995;36:718-724.
73. mTc-MDP: an overview of the experience at the National Cancer Institute of Napoli. Tumori 1997;83:515-519.
74. mTc sestamibi. Ann Nucl Med 1999;13: 453-456.
75. mTc MDP scintimammography in the evaluation of breast masses. Ann Nucl Med 2000;14:39-46.
76. m DTPA breast scintigraphy: where does it stand? Radiol Diagn 1978;19:512-515.
77. m diethylene triamine pentacetic acid: prospective blind evaluation. Br J Surg 1981;68:147-149.
78. mTc diethylene triamine pentacetic acid for the detection of malignant disease. Br J Surg 1986;73:613-616.
79. m pertechnatate in a nursing other with breast cancer. Clin Nucl Med 1990;15:264-265.
80. mTc sulfur colloid by a breast carcinoma. Clin Nucl Med 1990;15:432-433.
81. Jing JM, Kim EE, Moulopoulos L, et al. Primary breast lymphoma detected by SPECT using gallium 67-citrate. J Nucl Med 1995;36: 236-237.
82. 111In pentetreotide scintigraphy in breast cancer. J Nucl Med 1996;37:622-626.
83. Van Eijck CHJ, Krenning EP, Bootsma A, et al. Somatostatin scintigraphy in primary breast cancer. Lancet 1994;343:640-643.
84. Van de Wiele C, De Vos F, Slegers G Van Belle S, Dierckx RA. Radiolabelled estradiol derivatives to predict response to hormonal treatment in breast cancer. Eur J Nucl Med 2000;27:1421-1433.
85. Bruce DM, Evans NT, Heys SD, et al. Positron emmisssion tomography: 2-deoxy-2- 18[F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 1995;21:280-283.
86. Crowe JP, Adler LP, Shenk RR, et al. Positron emisssion tomography comparison and breast masses: with clinical, mammographic and pathological findings. Ann Surg Oncol 1994;1:132-140.
87. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic Assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36: 1766-1774.
88. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992;216:27-34.
89. Wahl RL. Overview of the current status of PET in breast cancer imaging. Q J Nucl Med 1998;42:1-7.
90. Minn H. Soini 1: [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15:61-66.
91. Wahl RL, Cody R, Hutchins GD, Mudgett E. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabelled glucose analog 2-[F-18]-fluoro-deoxy-2-D-glucose [FDG]. Radiology 1991;179:765-770.
92. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18]-2-deoxy-2-fluoro-D- glucose PET. Radiology 1993;187:743-750.
93. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with florine-18-deoxyglucose in the detection and staging or breast cancer. Cancer 1993;71:3920-3925.
94. Scheidhauer K, Scharl A, Pietrzyk U, et al. Qualitative [18F] FDG positron emission tomography in Primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996;23:618-623.
95. Avril N, Dose J, Janicke F, et al. Metabolic characterisation of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-1857.
96. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18:3495-1502.
97. Bassa PE, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorondeoxyglucose in breast cancer. J Nucl Med 1996;37:931-938.
98. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-2111.
99. Ahmad A, Barrington S, Maisey M, Rubens RD. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999;79:478-482.
100. 11C-methionine in breast cancer studies by PET. An association with the size of S-phase fraction. Br J Cancer 1991;64:1121-1124.
101. Inoue T, Kim EE, Wong FC, et al. Comparison of 18[F] flurodeoxy-glucose and C-11-methionine PET in detection of malignant tumours. J Nucl Med 1996;37:1472-1476.
102. Mintun MA, Welch MJ, Seigel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45-48.
103. Dehdashti F, McGuire AH, Van Brocklin HF, et al. Assessment of 21 [18f] fluoro-16-ethyl-19-norprogesterone as a positron emitting radiopharmaceutical for the detection of progestin receptors on human breast carcinomas. J Nucl Med 1991;32: 1532-1537.
104. Cimitan M, et al. The use of thallium-201 in the preoperative detection of breast cancer: an adjunct to mammography and ultrasonography. Eur J Nucl Med 1995;22:1110-1117.